Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Is TEVA a good investment?
Teva Pharmaceutical Industries Limited (TEVA) has a Plutrex AI rating of 48.0/100 as of November 09, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Near-term EPS recovery momentum: 51.7% forward EPS growth (vs. industry 38.16%) driven by cost restructuring ($700M savings), legal settlement clearing, and branded drug ramp (Austedo, WELTRUZA) creates genuine near-term earnings inflection — the single most compelling relative advantage vs. peers. Main concern: Valuation catastrophically worsened since prior report: P/E expanded from 65.71x to 100.33x (+52.7%), PEG from 11.84x to 16.50x (+39.4%), while revenue growth deteriorated from -0.8% to -1.9% — the stock is now MORE expensive for a WORSE business; at industry-average P/E of 36.23x on current earnings, fair value is approximately $15-16, implying ~63% downside risk; risk/reward from $42.61 to analyst target $49.00 is only 15% upside vs. 63% downside = 0.24:1 ratio.
Investment Summary
TEVA at $42.61 represents a deteriorating risk/reward situation versus my prior report 14 days ago. The stock has RISEN 8.1% from $39.41 while simultaneously the P/E has expanded from 65.71x to 100.33x (+52.7%), PEG has ballooned from 11.84x to 16.50x (+39.4%), and revenue growth has worsened from -0.8% to -1.9%. I am paying MORE for a business that has gotten WORSE by every fundamental measure. The news backdrop is genuinely positive — Q3 profit beat estimates, CEO Francis confirmed 2027 growth guidance despite IRA headwinds on Austedo, and debt has been meaningfully halved since 2017 — but positive news does not justify a P/E of 100.33x for a company with 6.1% long-term EPS growth. The analyst consensus target of $49.00 implies only 15% upside from $42.61, against a downside scenario of ~62% if P/E normalizes to the industry average of 36.23x (implying ~$15-16 on current earnings). The core thesis remains: TEVA is a legitimate recovery story with real FCF ($1.236B), improving balance sheet (debt halved since 2017), and near-term EPS momentum (+51.7%), but the stock is priced for perfection at 100x earnings with 2.3x more leverage than peers, declining revenues, and long-term growth of only 6.1% vs. industry average 11.96%.
Key Strengths
- Near-term EPS recovery momentum: 51.7% forward EPS growth (vs. industry 38.16%) driven by cost restructuring ($700M savings), legal settlement clearing, and branded drug ramp (Austedo, WELTRUZA) creates genuine near-term earnings inflection — the single most compelling relative advantage vs. peers
- Genuine deleveraging trajectory: Debt halved since 2017 (per CEO commentary), cash rose from $3.655B to $4.085B quarter-over-quarter, FCF of $1.236B provides real debt service capacity — financial health is directionally improving even if D/E of 1.62x remains elevated vs. industry 0.69x
- Operating efficiency leadership: Operating margin 27.4% vs. industry average 22.96% (+19.3% premium) demonstrates TEVA's cost discipline exceeds peers; Q3 profit beat estimates confirms execution is matching expectations
Key Concerns
- Valuation catastrophically worsened since prior report: P/E expanded from 65.71x to 100.33x (+52.7%), PEG from 11.84x to 16.50x (+39.4%), while revenue growth deteriorated from -0.8% to -1.9% — the stock is now MORE expensive for a WORSE business; at industry-average P/E of 36.23x on current earnings, fair value is approximately $15-16, implying ~63% downside risk; risk/reward from $42.61 to analyst target $49.00 is only 15% upside vs. 63% downside = 0.24:1 ratio
- Structural revenue decline and leverage mismatch: Revenue growth -1.9% (vs. industry +2.56%) while carrying D/E of 1.62x (vs. industry 0.69x) means TEVA's debt burden is growing relative to its shrinking business — the company must generate earnings recovery from cost cuts and mix shift rather than revenue growth, which is a fragile and time-limited strategy; long-term 5-year EPS growth of 6.08% vs. industry 11.96% confirms the market correctly anticipates this dynamic
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
TEVA's fundamentals present the same bifurcated picture as prior report with key metrics worsening: P/E has expanded to 100.33x (up from 65.71x) vs. industry average 36.23x — a 177% premium that is wholly unjustified. PEG of 16.50x vs. industry 9.66x (+71% premium) using 5-year EPS growth of 6.08% (vs. industry 11.96%) confirms structural overvaluation. Revenue growth deteriorated to -1.9% vs. prior -0.8%, with peers growing at +2.56% — TEVA is losing ground. The gross margin of 53.5% (vs. industry 55.56%) and operating margin of 27.4% (vs. industry 22.96%) are genuine positives, but the net margin of only 2.9% exposes how $1.62 D/E ratio (vs. industry 0.69) destroys shareholder value through interest expense. FCF of $1.236B (down from prior $1.348B) and cash of $4.085B (up from $3.655B) are the primary positives — real cash generation enabling continued deleveraging. Historical earnings growth of -46.0% (vs. industry -22.45%) and historical EPS growth of -11.2% contrast sharply with the 51.7% forward EPS growth projection, which reflects easy comparisons and normalization rather than structural improvement. ROE of 6.65% vs. industry 2.84% looks favorable but is leverage-amplified and paired with P/B of 6.23x — paying 6.23x book for 6.65% ROE delivers ~1.07% return on investment through ROE alone.
News Sentiment
Teva Pharmaceutical is quietly staging one of the more intriguing comebacks in the drug industry — but whether investors are paying too much to watch it unfold is the real question. The Israeli generic drug giant just reported Q3 results that beat profit estimates, sending shares jumping as much as the top 6% of pharma stocks on the day, according to market trackers. CEO Richard Francis didn't stop there — he doubled down on growth guidance, telling investors the company expects to expand even further in 2027, despite headwinds from the U.S. Inflation Reduction Act threatening to squeeze pricing on its flagship Huntington's disease drug Austedo. That's a bold promise, and Wall Street is cautiously optimistic. Behind the headlines, there's a real transformation story unfolding. Teva's debt — once a crushing $35 billion burden from a disastrous 2016 acquisition — has been roughly halved since 2017, while the company's cash balance has been climbing and revenue is starting to rebound. The company's Q3 earnings call revealed management's confidence in its innovative pipeline, including schizophrenia treatment WELTRUZA. But here's the tension everyday investors need to understand: Teva's stock is trading at nearly 100 times earnings — roughly triple what comparable drug companies fetch — for a business where revenues are still declining. The recovery story is real, but at current prices, you're paying tomorrow's prices for a company still working its way back.
Risk Assessment
PRIMARY RISK: Valuation compression. At P/E 100.33x with 6.1% long-term EPS growth, any earnings miss, guidance cut, IRA headwind worse than expected (Austedo pricing pressure), or interest rate rise could trigger rapid multiple compression. P/E normalization to industry average 36.23x implies ~$15-16 stock price — a 63% drawdown. SECONDARY RISK: Revenue decline (-1.9%) with 1.62x D/E creates refinancing risk if FCF deteriorates. TERTIARY RISK: Generic pricing pressure — TEVA's core generics business faces structural commoditization that the innovative pipeline (WELTRUZA, Austedo) must offset. MITIGATION: The $4.085B cash position and $1.236B FCF provide real liquidity buffer. CEO guidance of 2027 growth despite IRA impact demonstrates management confidence. Wait for entry zone $29-$33 where FCF yield exceeds 7% and risk/reward becomes favorable at ~2.9:1 to analyst target.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is TEVA a halal stock?
No, Teva Pharmaceutical Industries Limited (TEVA) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for TEVA?
Teva Pharmaceutical Industries Limited (TEVA) has a Plutrex AI rating of 48.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is TEVA a good investment?
According to Plutrex AI, TEVA has a Hold rating (48.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in TEVA?
US stocks like TEVA can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in TEVA?
Plutrex AI identifies the main risks for TEVA by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.